Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Eli Lilly And Co (LLY) Price & Performance

ProShares UltraShort Bloomberg Natural Gas ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

ProShares UltraShort Bloomberg Natural Gas ETF vs Eli Lilly And Co — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.67 (market cap $141.25M), while Eli Lilly And Co trades at $1,175.95 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 7362.8× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Eli Lilly And Co for 93 Days on average.

KOLDLLY
Market Cap
$141.25M$1.04T
Volume
5,492,3673,064,878
Sector
Leveraged / InverseHealth
52-Week High
$49.39$1.28K
52-Week Low
$13.58$799.57
Typical Hold Time
10 Days93 Days
Enterprise Value
—$1.09T
Dividend Yield
—0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares UltraShort Bloomberg Natural Gas ETF

KOLD is trading at $24.475, down 1.47% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from record-high natural gas production and mild weather forecasts that are weighing on energy sector sentiment. Recent news highlights geopolitical tensions in the Middle East and supply dynamics affecting natural gas markets, creating volatility for energy-related investments.

The outlook remains cautious given the bearish technical indicators and fundamental pressures from oversupply conditions in natural gas markets. Investment opportunities exist for contrarian investors betting on geopolitical risk premiums, but risks include continued production growth and weather-dependent demand uncertainty that could pressure energy sector performance in the near term.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KOLD
100% Buy0% Sell
Avg holding period · 10 Days
LLY
22% Buy78% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About ProShares UltraShort Bloomberg Natural Gas ETF

KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.

Read more on KOLD →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →